Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade
NCT06238245Phase 2Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
01
Overview
A Phase 2 trial of antithymocyte globulin rabbit, cyclophosphamide in graft-versus-host disease (GVHD), sponsored by The Fifth Medical Center of the PLA General Hospital. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
antithymocyte globulin rabbitcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06238245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238245.